Loading
A phase 3 trial in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study is a phase 3, randomised interventional study registered as NCT05692999 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 1166 participants, started 2023-03-20 and due to reach its primary completion in 2029-01. Interventions recorded: Pembrolizumab 200 mg Q6W; Pemetrexed 500 mg/m^2 Q3W; Pembrolizumab 200 mg Q3W or 400 mg Q6W. Conditions listed: Metastatic Non-squamous Lung Cancer. Primary outcome: Overall survival. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC)". Sites: Belgium, France, Spain. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.